Packer M, McMurray JJ, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993–1004.
Uptake of new heart failure drug slow, say makers. http://www.cardiomyopathy.org/news%2D%2Dmedia/latest-news/post/126-uptake-of-new-heart-failure-drug-slow-say-makers. Updated November 6, 2015. Accessed 18 Oct, 2017.
Packer M. Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA. Eur J Heart Fail. 2016;18:1211–9.
Packer M, Armstrong WM, Rothstein JM, Emmett M. Sacubitril-valsartan in heart failure: why are more physicians not prescribing it? Ann Intern Med. 2016;165:735–6.
Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312–8.
Khan MS, Fonarow GC, Ahmed A, Greene SJ, Vaduganathan M, Khan H, et al. Dose of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and outcomes in heart failure: a meta-analysis. Circulation: Heart Failure. 2017;10:e003956.
Pablos-Mendez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA. 1998;279(3):222–5.